Примери за използване на Thromboembolic events на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Thromboembolic events.
Arterial thromboembolic events.
Thromboembolic events.
Venous and arterial thromboembolic events.
Thromboembolic events.
Syncope, hypertension, thromboembolic events.
Thromboembolic events- arterial and venous.
The overall incidence of cases of arterial thromboembolic events was 3.8%.
Venous Thromboembolic Events.
Patients should be closely monitored for thromboembolic events.
Venous thromboembolic events.
Doptelet was not studied in patients with prior thromboembolic events.
Venous thromboembolic events(VTE).
Thrombotic and embolic events Arterial thromboembolic events.
Venous thromboembolic events(VTEs).
The European Medicines Agency has completed a review of Octagam triggered by reports of serious thromboembolic events.
Venous thromboembolic events(VTEs).
The clinically most important adverse reactions reported in postmenopausal women treated with Raloxifen were venous thromboembolic events(see section 4.4), which occurred in less than 1% of treated patients.
Arterial thromboembolic events(ATE).
Thromboembolic events, including pulmonary embolism.
Vascular disorders Venous thromboembolic events have rarely been reported.
Thromboembolic events may lead to cardiac arrest.
Vascular disorders Venous thromboembolic events have rarely been reported.
Thromboembolic events, vasculitis(including peripheral vascular disorder).
Prevention of atherothrombotic and thromboembolic events in atrial fibrillation.
Venous thromboembolic events have rarely been reported.
Meta-analyses also indicate consistently a significantly increased relative risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin see section.
Venous thromboembolic events, predominantly deep vein thrombosis and pulmonary embolism^,◊.
There is a theoretical risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors.
Thromboembolic events have been reported with the use of angiotensin II in clinical trials.